Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy.

Zejula (niraparib) - GSK, J&J

Rubraca (rucaparib) - Pharma& Schweiz

5-fluorouracil - Generic mfg.

AMXI-5001 - AtlasMedx

Lynparza (olaparib) - Merck (MSD), AstraZeneca

cisplatin - Generic mfg.

Talzenna (talazoparib) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/38323288

Csaba J Peto; David M Jablons; Hannah Dutta; Hassan Lemjabbar-Alaoui; Nathan R Brand; Vivianne Ding; Yi-Wei Yang

Feb 7, 2024